Eiger's Zokinvy (ionafarnib) Receives EC's Marketing Authorization for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Shots:
- The EC has granted marketing authorization for Zokinvy in children & young adults with HGPS & processing-deficient PL. Zokinvy is expected to be available, after successful completion of the reimbursement discussions country-by-country
- The EC authorization was based on 2 pivotal trials which showed a 72% reduction in risk of death & extended life by an av. of 4.3yrs. in children & young adults with HGPS
- The marketing authorization will be valid in all 27 EU member states, Iceland, Liechtenstein & Norway. Zokinvy is the first approved treatment in the EU & is currently under the MHRA's review as part of the EC Decision Reliance Procedure
Ref: PRNewswire | Image: Eiger
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
